BioNTech to terminate mid-stage trial of mRNA cancer vaccine

BioNTech SE said on Friday it has ​decided to terminate the mid-stage trial ‌of its experimental mRNA-based cancer vaccine for patients with a type of colorectal cancer, ​sending the German firm's U.S...

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。